What Drives Us
Every life counts: Antimicrobial resistance (AMR) is a global threat. At Delta G Avaris, we face this challenge with a revolutionary approach: Phage therapy – to save lives, restore quality of life, and preserve the future of medicine.
Our Goal
Our Goal
Our goal is to combat antimicrobial resistance (AMR) using a holistic, personalized phage-therapy approach that spans the full pipeline from analysis to application.
Vision
Our Plan: From Pioneers to Full-Service Providers
What makes Delta G Avaris unique: Our founding team includes physicians who have already achieved successful results with phage therapy and played a key role in advancing the field through their clinical work. We are currently working and researching to bring this alternative to antibiotics into standard medical care. In the long term, we aim to become the leading full-service provider for personalized phage therapy.
Mission
Our First Step: Combating ESKAPE Pathogens
Our mission is to make phage therapy accessible to patients worldwide and integrate it into everyday medical practice. We aim to achieve this through precise, industrially scaled, GMP-certified active ingredient production and a reliable supply chain for the magistral treatment of ESKAPE pathogens.
Our Values
Mission & Values
Scientific Excellence
We commit to the highest scientific standards in all areas of our research.
Transparency
Open communication and transparent presentation of our research activities are fundamental pillars of our work.
Responsibility
Responsible handling of scientific findings and compliance with all regulatory requirements.
The Problem
Facts & Figures
AMR threatens to undo decades of medical progress. Our approach uses phages — natural viruses that specifically target bacteria and offer new hope where antibiotics fail.
4.95 Mio.
Deaths linked to AMR (2019)
Antimicrobial resistance was associated with approximately 4.95 million deaths worldwide, including 1.27 million directly caused by resistant infections.
10 Mio.
Projected deaths by 2050
Without countermeasures, AMR could cause up to 10 million deaths annually —
over 80%
Success rate in healing attempts
In individual healing attempts, our medical team has achieved a success rate of over 80% — including bacterial load reduction and eradication.
Our Team
Meet the people at Delta G Avaris who work on bacteriophage research.